Cargando…

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention

Cancer-associated fibroblasts constitute a vital subpopulation of the tumor stroma and are present in more than 90% of epithelial carcinomas. The overexpression of the serine protease fibroblast activation protein (FAP) allows a selective targeting of a variety of tumors by inhibitor-based radiophar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loktev, Anastasia, Lindner, Thomas, Burger, Eva-Maria, Altmann, Annette, Giesel, Frederik, Kratochwil, Clemens, Debus, Jürgen, Marmé, Frederik, Jäger, Dirk, Mier, Walter, Haberkorn, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2019
Materias:	Theranostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785792/ https://www.ncbi.nlm.nih.gov/pubmed/30850501 http://dx.doi.org/10.2967/jnumed.118.224469

Ejemplares similares

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
por: Loktev, Anastasia, et al.
Publicado: (2018)

Targeting of activated fibroblasts for imaging and therapy
por: Lindner, Thomas, et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

(18)F-labeled tracers targeting fibroblast activation protein
por: Lindner, Thomas, et al.
Publicado: (2021)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
por: Funase, Yuichi, et al.
Publicado: (2021)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review
por: Windisch, Paul, et al.
Publicado: (2020)

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging
por: Kessel, Katharina, et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review
por: Windisch, Paul, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas
por: Dittmar, Jan Oliver, et al.
Publicado: (2017)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

(68)Ga-FAPI-PET/CT in patients with various gynecological malignancies
por: Dendl, Katharina, et al.
Publicado: (2021)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

Peptide-Based Targeting of the Platelet-Derived Growth Factor Receptor Beta
por: Askoxylakis, Vasileios, et al.
Publicado: (2012)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

A New Peptide Ligand for Targeting Human Carbonic Anhydrase IX, Identified through the Phage Display Technology
por: Askoxylakis, Vasileios, et al.
Publicado: (2010)

Challenges in Optimizing a Prostate Carcinoma Binding Peptide, Identified through the Phage Display Technology
por: Askoxylakis, Vasileios, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5mp5vn6ai5hdkl4640aolju20i